MA27443A1 - Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) - Google Patents

Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)

Info

Publication number
MA27443A1
MA27443A1 MA28157A MA28157A MA27443A1 MA 27443 A1 MA27443 A1 MA 27443A1 MA 28157 A MA28157 A MA 28157A MA 28157 A MA28157 A MA 28157A MA 27443 A1 MA27443 A1 MA 27443A1
Authority
MA
Morocco
Prior art keywords
tgf
thiazoles
transforming growth
inhibitors
oxazoles
Prior art date
Application number
MA28157A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27443A1 publication Critical patent/MA27443A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

REVENDICATION DE PRIORITES US 18 Septembre 2002 60/412,120 US 16 Mai 2003 60/471,265 US 2 Juillet 2003 60/484,581 Voir en annexe le titre de l'invention et le texte de l'abrégé Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (TGF) Des oxazoles et thiazoles nouveaux, y compris leurs dérivés, des intermédiaires pour leur préparation, des compositions pharmaceutiques les contenant, et leur utilisation en médecine sont décrits. Les composés de la présente invention sont de puissants inhibiteurs de la voie de transmission de signal du facteur de croissance transformant ("TGF")-(bêta). Ils sont utiles dans le traitement de divers états pathologiques en rapport avec le TGF, comprenant, par exemple, le cancer et des maladies fibrotiques.
MA28157A 2002-09-18 2005-03-18 Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) MA27443A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41212002P 2002-09-18 2002-09-18
US47126503P 2003-05-16 2003-05-16
US48458103P 2003-07-02 2003-07-02

Publications (1)

Publication Number Publication Date
MA27443A1 true MA27443A1 (fr) 2005-07-01

Family

ID=32034216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28157A MA27443A1 (fr) 2002-09-18 2005-03-18 Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)

Country Status (28)

Country Link
US (1) US7273936B2 (fr)
EP (1) EP1542994B1 (fr)
JP (1) JP4518956B2 (fr)
KR (1) KR20050057415A (fr)
CN (1) CN1681810A (fr)
AP (1) AP2005003261A0 (fr)
AR (1) AR041273A1 (fr)
AT (1) ATE430147T1 (fr)
AU (1) AU2003256003A1 (fr)
BR (1) BR0314383A (fr)
CA (1) CA2499429C (fr)
CO (1) CO5550473A2 (fr)
CR (1) CR7743A (fr)
DE (1) DE60327443D1 (fr)
EA (1) EA200500354A1 (fr)
ES (1) ES2323421T3 (fr)
HR (1) HRP20050250A2 (fr)
IS (1) IS7711A (fr)
MA (1) MA27443A1 (fr)
MX (1) MXPA05002332A (fr)
NO (1) NO20051838L (fr)
OA (1) OA12926A (fr)
PA (1) PA8582701A1 (fr)
PE (1) PE20040987A1 (fr)
PL (1) PL375975A1 (fr)
TW (1) TW200413362A (fr)
UY (1) UY27978A1 (fr)
WO (1) WO2004026863A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
JP4547271B2 (ja) * 2002-09-18 2010-09-22 ファイザー・プロダクツ・インク トランスフォーミング増殖因子（ｔｇｆ）阻害剤としての新規イミダゾール化合物
HRP20050247A2 (en) * 2002-09-18 2005-10-31 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313914D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
SG155222A1 (en) * 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
WO2006028029A1 (fr) * 2004-09-07 2006-03-16 Sankyo Company, Limited Dérivé de biphényle substitué
CA2580857A1 (fr) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
AR051091A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CA2580762A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
EP2289510A1 (fr) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques pour le traitement des maladies induites par des enzymes stearoyl-coa desaturase
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1807085B1 (fr) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'agents thérapeutiques
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007070866A2 (fr) * 2005-12-16 2007-06-21 Alcon, Inc. Controle de la pression intraoculaire a l'aide d'agents de modulation d'alk5
WO2008150827A1 (fr) * 2007-05-29 2008-12-11 Smithkline Beecham Corporation Dérivés de naphtyridine en tant qu'inhibiteurs de p13 kinase
WO2009111502A2 (fr) 2008-03-03 2009-09-11 University Of Notre Dame Du Lac Composés anticancéreux, synthèse de ceux-ci, et procédés utilisant ceux-ci
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
HRP20201384T1 (hr) 2014-01-01 2020-11-27 Medivation Technologies Llc Spojevi i postupci njihove upotrebe
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN105585565B (zh) * 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN106243012A (zh) * 2016-08-02 2016-12-21 北方民族大学 新型吲哚类衍生物及其制备方法
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途
EP4061352A4 (fr) 2019-11-19 2024-02-28 Trevena, Inc. Composés et procédés de préparation de composés modulateurs de s1p1
CN115466260B (zh) * 2022-09-06 2023-10-13 延边大学 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486009T2 (de) 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
EP0983260A2 (fr) 1997-05-22 2000-03-08 G.D. Searle & Co. PYRAZOLES 3(5)-HETEROARYL SUBSTITUEES UTILISEES COMME INHIBITEURS DE KINASE p38
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE60001229T2 (de) * 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
EP1205478A4 (fr) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd INHIBITEURS DE p38MAP KINASE
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
JP2004517068A (ja) 2000-11-16 2004-06-10 スミスクライン・ビーチャム・コーポレイション 化合物
EP1354603A1 (fr) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Co-prescriptions
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
WO2002062787A1 (fr) 2001-02-02 2002-08-15 Glaxo Group Limited Pyrazoles utilises comme inhibiteurs du tgf
JPWO2002062775A1 (ja) 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
JP2004521915A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ過剰発現に対するピラゾール誘導体
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
CA2450400A1 (fr) 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Compositions medicinales
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2004013135A1 (fr) 2002-07-31 2004-02-12 Smithkline Beecham Corporation Derives de c2-phenylpyridine-4-yl en tant qu'inhibiteurs d'alk5
GB0217787D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
HRP20050247A2 (en) 2002-09-18 2005-10-31 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
PL375973A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
CA2497971A1 (fr) 2002-09-18 2004-04-01 Pfizer Products Inc. Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf)
JP4547271B2 (ja) 2002-09-18 2010-09-22 ファイザー・プロダクツ・インク トランスフォーミング増殖因子（ｔｇｆ）阻害剤としての新規イミダゾール化合物

Also Published As

Publication number Publication date
IS7711A (is) 2005-02-24
PA8582701A1 (es) 2004-04-23
OA12926A (en) 2006-10-13
US7273936B2 (en) 2007-09-25
CA2499429C (fr) 2010-09-21
NO20051838L (no) 2005-04-15
CA2499429A1 (fr) 2004-04-01
ATE430147T1 (de) 2009-05-15
EP1542994B1 (fr) 2009-04-29
TW200413362A (en) 2004-08-01
AR041273A1 (es) 2005-05-11
JP4518956B2 (ja) 2010-08-04
AU2003256003A1 (en) 2004-04-08
WO2004026863A8 (fr) 2005-04-21
CR7743A (es) 2005-06-15
CO5550473A2 (es) 2005-08-31
ES2323421T3 (es) 2009-07-15
WO2004026863A1 (fr) 2004-04-01
UY27978A1 (es) 2004-04-30
BR0314383A (pt) 2005-07-19
DE60327443D1 (de) 2009-06-10
AP2005003261A0 (en) 2005-03-31
EP1542994A1 (fr) 2005-06-22
PE20040987A1 (es) 2004-12-27
CN1681810A (zh) 2005-10-12
HRP20050250A2 (en) 2005-10-31
EA200500354A1 (ru) 2005-10-27
PL375975A1 (en) 2005-12-12
JP2006502235A (ja) 2006-01-19
MXPA05002332A (es) 2005-06-08
KR20050057415A (ko) 2005-06-16
US20040110797A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
MA27443A1 (fr) Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27441A1 (fr) Composes d'imidazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27440A1 (fr) Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf)
MA27442A1 (fr) Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27444A1 (fr) Derives d'isothiazole et d'isoxazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
NZ542622A (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA27156A1 (fr) NUCLEOSIDES 3- β-D-RIBOFURANOSYLTHIAZOLO[4,5-d] PYRIDIMINE ET LES UTILISATIONS DE CELLES-CI
ATE402929T1 (de) Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
MA27121A1 (fr) Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol
MA26946A1 (fr) Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases.
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
AP1408A (en) Phenyl yanthine derivatives.
MA30514B1 (fr) Nouveaux composes.
SE9902987D0 (sv) Novel compounds
MXPA05008148A (es) Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf).
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA27451A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
FR2716883B1 (fr) Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
SE9903894D0 (sv) Novel compounds